TWI788343B - 治療用化合物 - Google Patents

治療用化合物 Download PDF

Info

Publication number
TWI788343B
TWI788343B TW107113171A TW107113171A TWI788343B TW I788343 B TWI788343 B TW I788343B TW 107113171 A TW107113171 A TW 107113171A TW 107113171 A TW107113171 A TW 107113171A TW I788343 B TWI788343 B TW I788343B
Authority
TW
Taiwan
Prior art keywords
methyl
pyrazol
oxo
pyridin
img
Prior art date
Application number
TW107113171A
Other languages
English (en)
Chinese (zh)
Other versions
TW201841900A (zh
Inventor
萊尼 崔羅斯
胡安曼努爾 貝坦科特
陶費吉 甘努尼
麥可布雷南 華勒斯
阿莫克 柏盧爾
Original Assignee
美商塞爾基因定量細胞研究公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商塞爾基因定量細胞研究公司 filed Critical 美商塞爾基因定量細胞研究公司
Publication of TW201841900A publication Critical patent/TW201841900A/zh
Application granted granted Critical
Publication of TWI788343B publication Critical patent/TWI788343B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW107113171A 2017-04-18 2018-04-18 治療用化合物 TWI788343B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762486894P 2017-04-18 2017-04-18
US62/486,894 2017-04-18
US201862657456P 2018-04-13 2018-04-13
US62/657,456 2018-04-13

Publications (2)

Publication Number Publication Date
TW201841900A TW201841900A (zh) 2018-12-01
TWI788343B true TWI788343B (zh) 2023-01-01

Family

ID=63791349

Family Applications (2)

Application Number Title Priority Date Filing Date
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物
TW107113171A TWI788343B (zh) 2017-04-18 2018-04-18 治療用化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW111146299A TW202332436A (zh) 2017-04-18 2018-04-18 治療用化合物

Country Status (5)

Country Link
US (4) US10617680B2 (enExample)
EP (1) EP3612522A4 (enExample)
JP (2) JP2020516672A (enExample)
TW (2) TW202332436A (enExample)
WO (1) WO2018195155A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10617680B2 (en) * 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
AU2019295790B2 (en) * 2018-06-29 2023-07-13 Forma Therapeutics, Inc. Inhibiting creb binding protein (CBP)
GB201905721D0 (en) 2019-04-24 2019-06-05 Univ Dundee Compounds
TW202304303A (zh) 2021-04-13 2023-02-01 美商富曼西公司 殺真菌之吡啶酮
IL309651A (en) 2021-06-29 2024-02-01 Tay Therapeutics Ltd History Pyrolopyridone is useful in the treatment of cancer
WO2025010291A2 (en) * 2023-07-03 2025-01-09 The General Hospital Corporation Targeted epigenetic therapies for disorders of progranulin deficiency

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3406329A1 (de) * 1984-02-22 1985-08-22 Merck Patent Gmbh, 6100 Darmstadt Pyridone
EP0825989A1 (en) 1995-05-19 1998-03-04 G.D. Searle & Co. Substituted oxazoles for the treatment of inflammation
JPH11508267A (ja) * 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
JP3760957B2 (ja) 1996-03-05 2006-03-29 信越化学工業株式会社 新規スルホニウム塩及び化学増幅ポジ型レジスト材料
CA2376835C (en) * 1999-07-02 2009-09-15 Eisai Co., Ltd. Condensed imidazole compounds and a therapeutic agent for diabetes mellitus
AU2002306868A1 (en) 2001-03-28 2002-10-15 Pharmacia Corporation Therapeutic combinations for cardiovascular and inflammatory indications
AU2004259755A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
AR045731A1 (es) * 2003-08-06 2005-11-09 Vertex Pharma Compuestos de aminotriazol utiles como inhibidores de quinasas de proteinas
KR20070008674A (ko) * 2004-04-01 2007-01-17 아스테라스 세이야쿠 가부시키가이샤 피라진 유도체, 및 아데노신 길항제로서의 이의 약학적용도
EP1604988A1 (en) * 2004-05-18 2005-12-14 Sanofi-Aventis Deutschland GmbH Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
WO2006137465A1 (ja) * 2005-06-24 2006-12-28 Shionogi & Co., Ltd. 含窒素複素環誘導体
WO2007026950A1 (en) * 2005-09-01 2007-03-08 Astellas Pharma Inc. Pyridazinone derivatives used for the treatment of pain
CA2623813A1 (en) * 2005-10-03 2007-04-12 Ono Pharmaceutical Co., Ltd. Nitrogen-containing heterocyclic compound and pharmaceutical application thereof
KR101352973B1 (ko) 2005-10-26 2014-01-22 삼성에스디아이 주식회사 연료전지용 탈황흡착제 및 이를 이용한 탈황방법
KR20080109841A (ko) * 2006-03-10 2008-12-17 뉴로젠 코포레이션 피페라지닐 옥소알킬 테트라히드로이소퀴놀린 및 관련유사체
CN101426774B (zh) * 2006-04-19 2012-04-25 安斯泰来制药有限公司 唑类甲酰胺衍生物
WO2007139150A1 (ja) * 2006-05-30 2007-12-06 The University Of Tokushima ＴＮＦα阻害物質を含有してなる抗インフルエンザウイルス剤
WO2008039882A1 (en) 2006-09-30 2008-04-03 Sanofi-Aventis U.S. Llc A combination of niacin and a prostaglandin d2 receptor antagonist
TW200906825A (en) 2007-05-30 2009-02-16 Scripps Research Inst Inhibitors of protein kinases
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
WO2009158393A1 (en) * 2008-06-25 2009-12-30 Envivo Pharmaceuticals, Inc. 1, 2 disubstituted heterocyclic compounds
AP2011005824A0 (en) 2009-01-26 2011-08-31 Intermune Inc Methods for treating acute myocardial infarctions and associated disorders.
GB0919380D0 (en) * 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
AU2011206621B2 (en) * 2010-01-12 2016-04-14 Ab Science Thiazole and oxazole kinase inhibitors
WO2012020786A1 (ja) 2010-08-11 2012-02-16 日本新薬株式会社 医薬組成物
US9481670B2 (en) 2011-01-25 2016-11-01 Sphaera Pharma Pte. Ltd. Triazine compounds
JP2014122161A (ja) * 2011-03-31 2014-07-03 Astellas Pharma Inc ピラゾール化合物
US8809372B2 (en) * 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
CN104470918A (zh) 2012-05-30 2015-03-25 日本新药株式会社 芳香族杂环衍生物及医药
MX2014015156A (es) * 2012-06-12 2015-08-06 Abbvie Inc Derivados de piridinona y piridazinona.
AU2013365926B9 (en) * 2012-12-21 2019-01-17 Zenith Epigenetics Ltd. Novel heterocyclic compounds as bromodomain inhibitors
KR20150126696A (ko) 2013-03-12 2015-11-12 애브비 인코포레이티드 디하이드로-피롤로피리디논 브로모도메인 억제제
WO2014140077A1 (en) 2013-03-14 2014-09-18 Glaxosmithkline Intellectual Property (No.2) Limited Furopyridines as bromodomain inhibitors
CN105263932B (zh) * 2013-03-28 2018-01-09 武田药品工业株式会社 杂环化合物
EP2991977B1 (en) 2013-05-01 2020-07-22 F.Hoffmann-La Roche Ag C-linked heterocycloalkyl substituted pyrimidines and their uses
BR112016015311B1 (pt) 2014-01-09 2023-01-24 Orion Corporation Compostos derivados heterocíclicos bicíclicos, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar uma doença associada com bromodomínio
KR102373700B1 (ko) * 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
SG11201609981RA (en) 2014-06-04 2016-12-29 Thomas Helledays Stiftelse För Medicinsk Forskning Mth1 inhibitors for treatment of inflammatory and autoimmune conditions
BR112017004704A2 (pt) * 2014-09-17 2018-01-23 Verseon Corp composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo
WO2016047678A1 (ja) * 2014-09-25 2016-03-31 武田薬品工業株式会社 複素環化合物
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
AR104259A1 (es) * 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
EA201890307A1 (ru) * 2015-07-15 2018-10-31 Ориджин Дискавери Текнолоджиз Лимитед Индазольные и азаиндазольные соединения как ингибиторы irak-4
EP3322409A4 (en) * 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS
CA2995325A1 (en) * 2015-08-12 2017-02-16 Mochida Pharmaceutical Co., Ltd. Isothiazole derivative
CA3129180A1 (en) * 2015-09-21 2017-03-30 Plexxikon Inc. Heterocyclic compounds and uses thereof
JP2019513804A (ja) 2016-04-18 2019-05-30 セルジーン クオンティセル リサーチ，インク． 治療用化合物
AU2017300336B2 (en) 2016-07-18 2021-03-11 National Institute Of Biological Sciences, Beijing Apoptosis inhibitors
US10617680B2 (en) 2017-04-18 2020-04-14 Celgene Quanticel Research, Inc. Therapeutic compounds
AR111479A1 (es) 2017-04-18 2019-07-17 Celgene Quanticel Res Inc Compuestos derivados de piridina y pirazol

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130109652A1 (en) * 2004-09-17 2013-05-02 Addex Pharmaceuticals S.A. Novel pyridinone derivatives and their use as positive allosteric modulators of mglur2-receptors
US20090054434A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Isoquinolone derivatives as phosphodiesterase 10 inhibitors
WO2014055548A1 (en) * 2012-10-02 2014-04-10 Intermune, Inc. Anti-fibrotic pyridinones
WO2015058160A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals, Inc. Bromodomain inhibitors

Also Published As

Publication number Publication date
JP2023088901A (ja) 2023-06-27
WO2018195155A1 (en) 2018-10-25
US20180296543A1 (en) 2018-10-18
US11020380B2 (en) 2021-06-01
US10617680B2 (en) 2020-04-14
TW201841900A (zh) 2018-12-01
US11890275B2 (en) 2024-02-06
US20200163946A1 (en) 2020-05-28
TW202332436A (zh) 2023-08-16
EP3612522A4 (en) 2021-07-07
EP3612522A1 (en) 2020-02-26
JP2020516672A (ja) 2020-06-11
US20210205284A1 (en) 2021-07-08
US20240293381A1 (en) 2024-09-05

Similar Documents

Publication Publication Date Title
TWI788343B (zh) 治療用化合物
US11884680B2 (en) Bromodomain inhibitors
CN109195602B (zh) 用作免疫调节剂的对称或半对称化合物
EP2049515B1 (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis
TWI469983B (zh) 用於治療神經病症之咪唑並［５，１－ｆ］［１，２，４］三類
US10336697B2 (en) Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors
TW201739744A (zh) 治療用化合物
JP2010505957A (ja) 糖尿病に対して使用されるｎ−アリールピラゾール化合物
KR20130062951A (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
KR20130130030A (ko) Vps34 억제제로서의 비-헤테로아릴 화합물
TW202041498A (zh) 抑制ｐｇｅ２／ｅｐ４信號傳導的化合物、其製備方法及其在醫藥上的應用
US11053251B2 (en) GPR35 modulators
KR20210022646A (ko) 시아노트리아졸 화합물 및 이의 용도
JP2025506446A (ja) 特定の化学物質、組成物、および方法
US20250345310A1 (en) Modulators of tnf-alpha activity
HK1131134B (en) Triazolyl pyridyl benzenesulfonamides as ccr2 or ccr9 modulators for the treatment of atherosclerosis

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees